Sagent Pharmaceuticals (Nasdaq: SGNT ) reported earnings on Feb. 14. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Sagent Pharmaceuticals met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue expanded and GAAP earnings per share expanded to zero.
Margins increased across the board.
Sagent Pharmaceuticals notched revenue of $53.2 million. The eight analysts polled by S&P Capital IQ predicted a top line of $53.1 million on the same basis. GAAP reported sales were 9.7% higher than the prior-year quarter's $48.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.00. The nine earnings estimates compiled by S&P Capital IQ anticipated -$0.19 per share. GAAP EPS dropped to zero from the prior-year quarter's -$0.33.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 21.8%, 1,250 basis points better than the prior-year quarter. Operating margin was -1.5%, 1,180 basis points better than the prior-year quarter. Net margin was -0.1%, 1,870 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $57.8 million. On the bottom line, the average EPS estimate is -$0.04.
Next year's average estimate for revenue is $242.7 million. The average EPS estimate is $0.09.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sagent Pharmaceuticals is hold, with an average price target of $19.44.